CYTOKINETICS, INCORPORATED
About CYTOKINETICS, INCORPORATED
Cytokinetics, Incorporated is a specialty cardiovascular biopharmaceutical company focused on the discovery and development of therapeutic agents that modulate muscle function for the treatment of debilitating diseases. It builds on over 25 years of scientific innovations in muscle biology and is advancing a pipeline including aficamten for potential commercialization. The company is publicly traded on Nasdaq under CYTK and headquartered in South San Francisco, California.
- 🔗 Cytokinetics, Incorporated - Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
- 🔗 Cytokinetics - 2026 Company Profile, Funding, Competitors & Financials - Tracxn
- 🔗 Why Cytokinetics, Incorporated (CYTK) Is the Best Mid Cap Biotech Stock to Buy
- 🔗 Cytokinetics, Incorporated - Cytokinetics Announces Proposed Public Offering of Common Stock
- 🔗 Cytokinetics plans $650M public stock offering | CYTK Stock News
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- Announced up to $575 million strategic funding collaboration with Royalty Pharma in May 2024
- Proposed $650 million public offering of common stock in May 2026
- Holds approximately $1.3 billion in cash and investments as of September 2024
- Advancing commercialization of aficamten and cardiovascular R&D pipeline
Ask StreetZero about CYTOKINETICS, INCORPORATED
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account